Replies to post #58979 on Biotech Values

[ThomasS]

ZGEN: I'm a proponent of shareholder value via clinical progress, as I'd imagine you are. However, I understand your comments as presented.
Interestingly, post-earnings/after-market it appears that someone misunderstood the 2008 rev guidance, which DID NOT include any RECOTHROM sales. Otherwise, the guidance is above forecast, imo.

[ThomasS]

ZGEN: <<IMO, they do not have the type of management team that would likely delay "progress.">>

That makes another thing we can disagree about today, then!

from SeekingAlpha CC transcript:

"We've also restructured our remaining personnel to support our long-term goal to focus on assets which are owned exclusively by ZymoGenetics and to take these programs at least through the proof-of-concept stage in the clinic. This will create greater value for our shareholders and supports our mission to develop innovative biotherapeutics. We believe these decisions will allow us to maximize our return on R&D investment."